News News and Resources

Pace® Life Sciences, a U.S.-based contract research, development, and manufacturing organisation (CRDMO) and FDA-registered GMP analytical testing laboratory, has reopened its 33,000 square foot facility in Salem, New Hampshire. The upgraded site now serves as a Centre of Excellence for

Bionova Scientific®, a biologics contract development and manufacturing organisation (CDMO) and subsidiary of Asahi Kasei, has opened a 10,000 square-foot plasmid DNA (pDNA) development and production facility in The Woodlands, Texas. The site is designed to supply research-grade pDNA to

AbbVie has announced a $195 million investment in its North Chicago, Illinois, manufacturing site to expand domestic active pharmaceutical ingredient (API) production. The expansion is part of AbbVie’s broader plan to invest more than $10 billion in the U.S., aiming

Cohance Lifesciences has revealed a strategic investment of USD 10 million to grow its cGMP bioconjugation capabilities at NJ Bio, its subsidiary based in Princeton, New Jersey. The expansion aligns with Cohance’s global strategy to strengthen its contract research, development

Quantum BioPharma Ltd. has entered into an agreement with a leading contract development and manufacturing organisation (CDMO) to produce an oral formulation of Lucid-MS, the company’s investigational treatment for multiple sclerosis (MS). The oral formulation will be used in a

Sanner has announced a change in leadership as part of its strategic move to strengthen its position as a contract development and manufacturing organisation (CDMO) for medical devices and advanced pharmaceutical drug delivery systems. The company confirmed that CEO Dr.

ProBio, a contract development and manufacturing organisation (CDMO) specialising in gene and cell therapy, has introduced current Good Manufacturing Practice (cGMP) adeno-associated virus (AAV) manufacturing services at its 128,000 sq. ft. facility in Hopewell, New Jersey. The expansion is intended

WuXi Biologics has announced the launch of WuXia293Stable, a new platform designed for the development and manufacturing of complex biologics that are stably expressed in HEK293 cells. The technology targets innovative, difficult-to-express molecules, offering high titers, robust stability, and improved

Excellos, Lonza, and Akadeum Life Sciences have announced a new joint initiative to improve cell and gene therapy (CGT) manufacturing by prioritising starting material quality and exploring modular workflow integration. The collaboration aims to streamline production and reduce variability across

Sumitomo Chemical has announced that its subsidiary S-RACMO Co., Ltd., 66.6% owned by Sumitomo Chemical and 33.4% by Sumitomo Pharma, has completed construction of its third regenerative medicine and cell therapy manufacturing facility, known as CRAFT (Center for Regenerative Medicine